Blueprint Medicines Corp. (NASDAQ:BPMC)’s share price dropped 1.4% during trading on Friday . The stock traded as low as $27.22 and last traded at $27.24, with a volume of 63,851 shares trading hands. The stock had previously closed at $27.62.

BPMC has been the topic of several analyst reports. Cowen and Company reiterated a “buy” rating on shares of Blueprint Medicines Corp. in a report on Tuesday, May 10th. Canaccord Genuity initiated coverage on Blueprint Medicines Corp. in a report on Friday, August 5th. They set a “buy” rating and a $26.00 price target on the stock. Zacks Investment Research downgraded shares of Blueprint Medicines Corp. from a “buy” rating to a “hold” rating in a research note on Thursday, August 18th. Raymond James Financial Inc. initiated coverage on shares of Blueprint Medicines Corp. in a research note on Friday, May 27th. They issued an “outperform” rating and a $23.00 price objective on the stock. Finally, TheStreet upgraded shares of Blueprint Medicines Corp. from a “sell” rating to a “hold” rating in a research note on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $29.43.

The company’s 50-day moving average price is $24.21 and its 200 day moving average price is $19.67. The stock’s market cap is $742.75 million.

Blueprint Medicines Corp. (NASDAQ:BPMC) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.70) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.03. During the same period last year, the business posted ($0.81) EPS. The firm earned $7.07 million during the quarter, compared to analyst estimates of $4.41 million. The company’s revenue was up 163.0% on a year-over-year basis. On average, equities research analysts predict that Blueprint Medicines Corp. will post ($3.05) earnings per share for the current year.

In other Blueprint Medicines Corp. news, CEO Jeffrey W. Albers sold 17,000 shares of the firm’s stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $22.86, for a total value of $388,620.00. Following the completion of the sale, the chief executive officer now owns 76,494 shares of the company’s stock, valued at $1,748,652.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.